Skip to content
AnalystLens

ResMedRMD

Legal name
ResMed Inc.
Sector
Healthcare
Industry
Surgical & Medical Instruments & Apparatus
Exchange
NYSE

Stock Price $RMD

Latest filings

You are here#42 of 54 in Healthcare by market cap

Filing record · 2016–202610-K1410-Q338-K85

RMD filed 14 annual reports (10-K), 33 quarterly reports (10-Q) and 85 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Jul ’19Jul ’19
  3. Leadership change8-K · Oct ’21Oct ’21
  4. Leadership change8-K · Nov ’25Nov ’25

01—Key figures

Share Class
Source: 10-KFY2026
Source: 10-KFY2026
Source: 10-KFY2026
Source: 10-KFY2026

Revenue Trend

Year-over-year comparison from 10-K annual reports

  18. $5.65B
YoY changeLargest recent move+18.0%in FY23Latest +9.9%

Latest bar from 10-KFY2026Click a bar to open its SEC filing

View full history →
All RMD Financial Metrics62 metrics

Income Statement16

Balance Sheet26

Cash Flow15

Per Share5

02—Overview

ResMed Financial Overview 2022–2026

Updated Nov 4, 2026

ResMed's market value fell by $9.7 billiona, from $37.8 billion at the close of FY2025 to $28.1 billion at the close of FY2026, even though earnings per share rose to $10.43 from $9.51. That is the core thesis: the business kept compounding, and the multiple did the shrinking. The stock closed at $258.00 on the FY2025 date, or 27.1x earnings, then at $194.88 on the FY2026 date, or 18.7x.

The long-term record is hard to argue with. Revenue grew from $3.58 billion in FY2022 to $5.65 billionb in FY2026, and diluted EPS nearly doubled from $5.30 to $10.43. Gross margin widened from 56.6% to 61.1% over the same stretch. Growth in FY2026 held at 10%, with Sleep and Breathing Health up 10% to $4.98 billion. Residential Care Software lagged at 5% growth.

The balance sheet gives management room to act. Operating cash flow reached $1.81 billionc in FY2026. Cash of $1.47 billion sat against just $660 million of debt. The company returned $700 million through buybacks and $350 million through dividends. It also agreed to sell MatrixCare for $490 million in cash. Not everything was clean: Q4 2026 gross margin dipped to 58.8% on $41.9 million of Astral field safety expenses.

Recent Developments (Q4 2026 and Q1 2027)

Q1 2027 brought the MatrixCare close and a large capital return. Revenue rose 6% to $1.415 billiond, while Sleep and Breathing Health grew 8%. Non-GAAP gross margin gained 50 basis points to 62.5%. GAAP EPS rose 23% to $2.92, helped by a $62 million pre-tax divestiture gain. Operating income barely moved, at $453 million versus $447 million. Free cash flow fell 10% to $374 million on higher inventory. ResMed returned over $1.0 billion in the quarter, including a $450 million accelerated repurchase, and repaid $250 million of notes. Fiscal 2027 guidance held at $12.00 to $12.25 non-GAAP EPS. Audit work moves from KPMG to PricewaterhouseCoopers for FY2027.

The bull case: margins are expanding, debt is down to $410 millione, and buybacks shrink the share count. The bear case: core growth guidance of 5% to 7% is slower, and the Q1 2027 EPS beat leaned on a one-time gain. At 22.0x earnings as of the October 29, 2026 quarterly report date, the stock sits above the 18.7x year-end level. That price is not today's.

What to watch: Free cash flow and inventory trends against the 5% to 7% growth guide; ASR settlement by December 2026

03—Filings

Recent SEC Filings

  1. 8-KResMed 8-K Report, Financial Results (Oct 29, 2026)Resmed Inc. (NYSE: RMD, ASX: RMD) reported results for its first quarter of fiscal year 2027, the quarter ended September 30, 2026, in an press release furnished as Exhibit 99.1. Revenue rose 6% to $1.415 billion (7% on a core constant currency basis). GAAP diluted EPS was $2.92, up 23% from $2.37, and non-GAAP diluted EPS was $2.91, up 14% from $2.55. GAAP net income was $418.4 million versus $348.5 million a year earlier. Operating cash flow was $422 million and free cash flow was $374 million. The company returned more than $1.0 billion to shareholders through share repurchases and dividends during the quarter, with treasury stock purchases of $936.4 million, and completed the divestiture of the MatrixCare business. Revenue growth was led by Americas Sleep and Breathing Health (up 7% core constant currency) and Rest of World Sleep and Breathing Health (up 8%), while Residential Care Software rose 5% on a core constant currency basis. Non-GAAP gross margin expanded 50 basis points to 62.5%. Fiscal 2027 guidance was reaffirmed, with core constant currency revenue growth of 5% to 7%, reported revenue of $5.75 to $5.85 billion, and non-GAAP diluted EPS of $12.00 to $12.25, all unchanged from the August 6, 2026 guidance. The board declared a quarterly cash dividend of $0.66 per share, payable December 17, 2026 to holders of record on November 12, 2026, with an ex-dividend date of November 11, 2026. The company also announced that Carol Burt will become Lead Director effective November 15, 2026, following the planned retirement of Ron Taylor.
  2. 8-KResMed 8-K Report, Corporate Update (Sep 1, 2026)ResMed Inc. disclosed in this Form 8-K, dated September 1, 2026, that on August 31, 2026 it entered into an accelerated share repurchase (ASR) agreement with Citibank, N.A. to repurchase $450.0 million of its common stock. The repurchase is being made under a share repurchase authorization for an aggregate of 20,000,000 shares approved by the board of directors in February 2014. The company intends to fund the transaction with proceeds from the sale of its MatrixCare business and cash on hand. Under the agreement, ResMed will pay Citibank $450.0 million on September 3, 2026, and expects to receive on the same day an initial delivery of shares equal to 80% of $450.0 million divided by the closing price on September 2, 2026. The final share count will be based on the average daily volume weighted average price of the common stock over the term of the agreement, less a discount and subject to adjustments. At settlement, Citibank may deliver additional shares, or in certain circumstances ResMed may deliver shares or make a cash payment at its election. Final settlement is scheduled for December 2026, though Citibank may elect to complete it earlier. The filing states that this ASR transaction was contemplated in the fiscal year 2027 guidance the company issued during its Q4 FY26 earnings call on August 6, 2026.
  3. 8-KResMed 8-K Report, Auditor Change (Aug 17, 2026)ResMed Inc. (NYSE: RMD) filed this Current Report on Form 8-K dated August 17, 2026, disclosing two governance and accounting changes. First, under Item 4.01, the company dismissed KPMG LLP as its independent registered public accounting firm effective August 13, 2026, and appointed PricewaterhouseCoopers LLP as its new auditor, subject to completion of PwC's standard client acceptance procedures, for the fiscal year ending June 30, 2027. The filing states that KPMG's reports on the fiscal 2026 and 2025 consolidated financial statements contained no adverse opinion or disclaimer and were not qualified or modified, and that there were no disagreements or reportable events during the relevant periods. KPMG's letter to the SEC is referenced as Exhibit 16.1. Second, under Item 5.02, director Ronald Taylor informed the Board on August 13, 2026 that he will not stand for election at the 2026 Annual Meeting, expected to be held November 18, 2026, and will retire from the Board at that time. The filing states his decision is not due to any disagreement with the company on its operations, policies or practices. The Board appointed Carol Burt, who chairs the Nominating and Governance Committee, as lead director effective November 15, 2026. Per the attached press release (Exhibit 99.1), Taylor joined the Board in 2005 and had served as Lead Director since 2013. The filing describes a competitive review process by the Audit Committee for selecting the new auditor. It does not state a reason for the auditor change beyond that review, and it contains no financial results or operating figures.
  4. 8-KResMed 8-K Report, Financial Results (Aug 6, 2026)Resmed Inc. reported results for its fourth quarter and fiscal year ended June 30, 2026, in a press release furnished as Exhibit 99.1. Fourth-quarter revenue rose 9% to $1,464 million (8% in constant currency), and GAAP diluted earnings per share increased 2% to $2.64. Non-GAAP diluted earnings per share rose 16% to $2.95. For the full fiscal year, revenue increased 10% to $5,653 million, GAAP diluted EPS was $10.43, and non-GAAP diluted EPS was $11.17, an increase of 17%. Operating cash flow for the year was $1,806 million and free cash flow was $1,650 million. Fourth-quarter GAAP gross margin fell 200 basis points to 58.8%, reflecting $41.9 million of Astral field safety notification expenses, which the company excludes from its non-GAAP measures. GAAP income from operations declined 1% to $449 million, while non-GAAP income from operations rose 8% to $515 million. Fourth-quarter free cash flow decreased 21% to $404 million. The board declared a quarterly cash dividend of $0.66 per share, a 10% increase over the prior quarterly dividend, with a record date of August 20, 2026 and payment on September 24, 2026. The company also disclosed an agreement to sell its MatrixCare business, expected to close in the first quarter of fiscal 2027, and the completed acquisition of Noctrix Health. For fiscal 2027, the company is guiding to more than $1.85 billion in capital returned to shareholders through share repurchases and dividends.
  5. 8-KResMed 8-K Report, Financial Results (Jul 7, 2026)ResMed Inc. (NYSE: RMD) reported in an Item 2.02 Form 8-K filed July 7, 2026 that on June 30, 2026 it entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on healthcare, for $490 million in cash, subject to certain closing adjustments. The transaction is expected to close during the first quarter of fiscal year 2027, subject to required regulatory approvals and customary closing conditions. Resmed intends to use the net proceeds to return capital to shareholders, including through an accelerated share repurchase (ASR) program, and for general corporate purposes. According to the filing, MatrixCare represented approximately $220 million of revenue and approximately $55 million of non-GAAP operating profit based on preliminary full fiscal year 2026 results. Resmed expects transition services agreements to largely offset first-year post-closing stranded costs and intends to mitigate remaining stranded costs over time. The company also said its recently completed Noctrix acquisition is expected to contribute approximately $30 million of revenue and reduce non-GAAP diluted EPS by approximately $0.20 in fiscal year 2027. Resmed continues to expect its Residential Care Software (RCS) segment to accelerate to high single digit percentage year-over-year revenue growth, along with operating leverage, in fiscal 2027. It reiterated its fiscal 2026 outlook for non-GAAP gross margin, non-GAAP SG&A and R&D as a percentage of revenue, and non-GAAP tax rate, along with its fourth-quarter fiscal 2026 outlook for net interest income and planned share repurchases. Full fiscal 2027 guidance will be provided on the fourth-quarter fiscal 2026 earnings call on August 6, 2026.
View all 8-K filings →
View all filings (10-K, 10-Q, 8-K, proxy & more) →

04—See also

Related Companies

Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.